Quick Answer
IGC Pharma, Inc. reported Total Assets of $8.75 million for the year ending 2025.
- IGC Pharma, Inc. showed a decrease of -11.7% in Total Assets from 2024 to 2025.
- This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $17.49 million | Q4 2011: $35.10 million | Q3 2012: $24.22 million | Q4 2012: $21.44 million | Q2 2013: $18.58 million | Q3 2013: $18.54 million | Q4 2013: $18.19 million | Q2 2014: $21.61 million | Q3 2014: $21.19 million | Q4 2014: $21.26 million | Q2 2015: $20.58 million | Q3 2015: $18.82 million | Q4 2015: $18.40 million | Q2 2016: $18.50 million | Q3 2016: $18.86 million | Q4 2016: $11.17 million | Q2 2017: $9.44 million | Q3 2017: $9.99 million | Q4 2017: $11.34 million | Q2 2018: $11.52 million | Q3 2018: $16.55 million | Q4 2018: $37.16 million | Q2 2019: $33.51 million | Q3 2019: $32.89 million | Q4 2019: $31.10 million | Q2 2020: $28.30 million | Q3 2020: $26.35 million | Q4 2020: $24.16 million | Q2 2021: $34.44 million | Q3 2021: $33.84 million | Q4 2021: $31.29 million | Q2 2022: $24.17 million | Q3 2022: $21.96 million | Q4 2022: $20.07 million | Q2 2023: $15.67 million | Q3 2023: $16.51 million | Q4 2023: $11.26 million | Q2 2024: $10.59 million | Q3 2024: $10.37 million | Q4 2024: $9.08 million | Q1 2025: $8.75 million | Q2 2025: $7.94 million | Q3 2025: $9.74 million.
- Over the full 15 years of available data (2011 to 2025), IGC Pharma, Inc.'s Total Assets has declined by 51.8%.
- Historical annual values: Fiscal year 2025: $8.75 million | Fiscal year 2024: $9.90 million | Fiscal year 2023: $17.18 million | Fiscal year 2022: $26.83 million | Fiscal year 2021: $35.87 million | Fiscal year 2020: $28.98 million | Fiscal year 2019: $34.47 million | Fiscal year 2018: $10.85 million | Fiscal year 2017: $11.28 million | Fiscal year 2016: $18.86 million | Fiscal year 2015: $20.33 million | Fiscal year 2014: $17.73 million | Fiscal year 2013: $19.25 million | Fiscal year 2012: $25.26 million | Fiscal year 2011: $18.16 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: